SNDX - Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc Logo

SNDX - Syndax Pharmaceuticals Inc

https://syndax.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-09 (Snapshot)

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.

52W High
$22.50
52W Low
$8.58
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.72
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-105.26
EV/Revenue (<3 favorable)
12.84
P/S (TTM) (<3 favorable)
18.83
P/B (<3 favorable)
9.32
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
1.29%
Institutions (25–75% balanced)
120.97%
Shares Outstanding
86,142,000
Float
72,722,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
77,933,000
Gross Profit (TTM)
-185,420,000
EPS (TTM)
-3.89
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-1.83%
ROE (TTM) (>15% strong)
-1.13%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
9.85
Momentum
Bearish momentum
Value
0.9399
Previous
1.0790
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025